The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptomsJeffrey R. Stokes, Thomas B. Casale, Frances Hackman et al.|Journal of Allergy and Clinical Immunology|2011Cited by 59
Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patientsGerd Fätkenheuer, T.M. Jenkins, Gary Layton et al.|AIDS|2009Cited by 43
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjectsJohn D. Davis, Georges Weissgerber, Gary Layton et al.|British Journal of Clinical Pharmacology|2008Cited by 28
Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unitMichelle L. North, Anne K. Ellis, Terry J. Walker et al.|Allergy Asthma and Clinical Immunology|2014Cited by 22
Double blind randomized crossover trial of PF-03654764+fexofenadine in the environmental exposure unit (EEU)Michelle L. North, Anne K. Ellis, Terry Walker et al.|Allergy Asthma and Clinical Immunology|2014Cited by 3